GANX
USDGain Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$1.810
Максимум
$1.810
Минимум
$1.660
Объем
0.57M
Фундаментальные показатели компании
Рыночная капитализация
59.7M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.68M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.